LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - HC Wainwright increased their FY2024 earnings per share estimates for shares of LENZ Therapeutics in a note issued to investors on Thursday, November 7th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($2.01) per share for the year, up from their prior estimate of ($2.54). HC Wainwright has a "Buy" rating and a $38.00 price target on the stock. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for LENZ Therapeutics' Q4 2024 earnings at ($0.43) EPS, FY2025 earnings at ($2.13) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($0.55) EPS and FY2028 earnings at $0.55 EPS.
Several other research firms have also recently commented on LENZ. William Blair upgraded LENZ Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Piper Sandler reissued an "overweight" rating and set a $36.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Finally, Raymond James assumed coverage on LENZ Therapeutics in a research report on Friday, September 27th. They issued an "outperform" rating and a $37.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $35.40.
Check Out Our Latest Research Report on LENZ Therapeutics
LENZ Therapeutics Stock Performance
Shares of NASDAQ:LENZ traded up $0.68 during trading on Monday, reaching $35.75. The stock had a trading volume of 184,455 shares, compared to its average volume of 136,713. The business has a fifty day moving average price of $24.94 and a 200-day moving average price of $21.27. LENZ Therapeutics has a fifty-two week low of $14.07 and a fifty-two week high of $37.13.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09. During the same period last year, the business posted ($1.33) EPS.
Hedge Funds Weigh In On LENZ Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. American International Group Inc. purchased a new stake in LENZ Therapeutics during the 1st quarter worth $44,000. SG Americas Securities LLC purchased a new position in LENZ Therapeutics in the third quarter valued at about $107,000. GSA Capital Partners LLP purchased a new stake in LENZ Therapeutics during the 3rd quarter worth approximately $246,000. Squarepoint Ops LLC acquired a new position in shares of LENZ Therapeutics in the 2nd quarter valued at approximately $181,000. Finally, Rhumbline Advisers grew its holdings in LENZ Therapeutics by 265.6% during the 2nd quarter. Rhumbline Advisers now owns 16,812 shares of the company's stock worth $291,000 after acquiring an additional 12,214 shares in the last quarter. Hedge funds and other institutional investors own 54.32% of the company's stock.
LENZ Therapeutics Company Profile
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Further Reading
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
